Keros Therapeutics, Inc. (KROS): R&D Expense
$129.64M
Year ended 2025-12-31
$75.86M
Trailing 12 months to 2026-06-30
+14.1%
3-year compound annual growth
+30.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $129.64M | -25.3% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $173.63M | +28.4% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $135.26M | +55.0% | 2025-02-26, From 2023-01-01 |
| 2022-12-31 | $87.27M | +58.3% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $55.14M | +62.9% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $33.86M | +94.8% | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | $17.38M | n/a | 2021-03-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $129.64M | -25.3% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $523.00M | +16.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $62.36M | +65.6% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $135.97M | -17.0% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $173.14M | -14.2% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $62.07M | +13.0% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $285.20M | -18.1% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $81.18M | +278.9% |
| Harrow, Inc. (HROW) | 2025-12-31 | $20.94M | +71.2% |
Compare KROS, RCUS, AKBA, ANAB side by side · Screen every company in Pharmaceutical Preparations ↗